Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Silexion Therapeutics Corp Ordinary Shares

SLXN

Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.65 – $1.89
Volume 17,432
Market cap $1M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for SLXN.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for SLXN.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Silexion Therapeutics Announces 1-for-24 Reverse Share Split

Silexion Therapeutics announced a 1-for-24 reverse share split effective November 11, 2026, to regain compliance with Nasdaq's minimum bid price requirement and support its clinical progress with SIL204 in locally advanced pancreatic cancer. The company dosed its first patient in the Phase 2/3 trial in September 2026.

GlobeNewswire Inc.

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics announced the first patient has been successfully dosed in its Phase 2/3 clinical trial of SIL204, an RNAi therapy for locally advanced pancreatic cancer with KRAS mutations. The trial combines direct intratumoral EUS-guided delivery with subcutaneous dosing alongside standard chemotherapy. The study includes an initial safety cohort of ~18 patients followed by expansion to ~166 patients across Israel and Germany.

GlobeNewswire Inc.

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

Silexion Therapeutics has initiated GMP clinical manufacturing of SIL204, its next-generation siRNA therapy targeting mutated KRAS in pancreatic cancer, in collaboration with CDMO Catalent at its Limoges, France facility. The company received approval from Tel Aviv Sourasky Medical Center's Helsinki Ethics Committee for its planned Phase 2/3 trial in locally advanced pancreatic cancer, following earlier approvals from the Israeli Ministry of Health and a clinical trial application submission to Germany's BfArM.

GlobeNewswire Inc.

Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer

Silexion Therapeutics received formal written Scientific Advice from the German Federal Institute for Drugs and Medical Devices regarding its planned Phase 2/3 clinical trial for SIL204, a potential treatment for locally advanced pancreatic cancer. The guidance provides regulatory clarity and supports the company's planned trial initiation in Q2 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 11, 20261-for-24reverse split
May 29, 20261-for-10reverse split
Jul 29, 20251-for-15reverse split
Nov 29, 20241-for-9reverse split